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Abstract
Background: Up to a third of patients presenting medically unexplained physical symptoms in primary care may
have a somatoform disorder, of which undifferentiated somatoform disorder (USD) is the most common type.
Psychological interventions can reduce symptoms associated with USD and improve functioning. Previous research
has either been conducted in secondary care or interventions have been provided by general practitioners (GPs) or
psychologists in primary care. As efficiency and cost-effectiveness are imperative in primary care, it is important to
investigate whether nurse-led interventions are effective as well. The aim of this study is to examine the effectiveness
and cost-effectiveness of a short cognitive behavioural therapy (CBT)-based treatment for patients with USD provided
by mental health nurse practitioners (MHNPs), compared to usual care.
Methods: In a cluster randomised controlled trial, 212 adult patients with USD will be assigned to the intervention or
care as usual. The intervention group will be offered a short, individual CBT-based treatment by the MHNP in addition
to usual GP care. The main goal of the intervention is that patients become less impaired by their physical symptoms
and cope with symptoms in a more effective way. In six sessions patients will receive problem-solving treatment. The
primary outcome is improvement in physical functioning, measured by the physical component summary score of the
RAND-36. Secondary outcomes include health-related quality of life measured by the separate subscales of the RAND-
36, somatization (PHQ-15) and symptoms of depression and anxiety (HADS). Problem-solving skills, health anxiety,
illness perceptions, coping, mastery and working alliance will be assessed as potential mediators. Assessments will be
done at 0, 2, 4, 8 and 12 months. An economic evaluation will be conducted from a societal perspective with quality of
life as the primary outcome measure assessed by the EQ-5D-5L. Health care, patient and lost productivity costs will be
assessed with the Tic-P.
Discussion: We expect that the intervention will improve physical functioning and is cost-effective compared to usual
care. If so, more patients might successfully be treated in general practice, decreasing the number of referrals to
specialist care.
(Continued on next page)
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Background
Physical symptoms that cannot be sufficiently explained
by organic pathology are commonly presented by pa-
tients in all health care settings [1, 2]. In primary care
up to one third of patients present these medically unex-
plained physical symptoms (MUPS) to the general prac-
titioner (GP) [3]. Most of these symptoms are self-
limiting, but some persist and cluster. Up to a third of
patients presenting with such symptoms in primary care
can be diagnosed with a somatoform disorder [3–5].
The most common type of somatoform disorder is un-
differentiated somatoform disorder (USD), including
patients who suffer from at least one impairing
unexplained physical symptom lasting longer than 6
months [6]. USD is associated with considerable
functional impairment and reduced quality of life, which
in turn results in a high illness burden. Anxiety and
depression are comorbid in at least 13.7% of the cases
[7, 8] and may aggravate symptoms and functional
limitations [5].
Additionally, USD is associated with high health care
costs due to frequent and excessive health care use, re-
peated diagnostic procedures and high lost productivity
costs [9, 10]. In 2010 the total costs of all somatoform
disorders in Europe amounted to €21 billion, which was
considered to be a conservative estimate [11, 12].
Previous research shows that only half of patients with
USD seek help from a mental health care provider [13].
However, several reviews on treatment of MUPS and
somatoform disorders show that cognitive behavioural
therapy (CBT) is effective, with moderate effect sizes
[14, 15]. Moreover, CBT interventions are effective in
treating anxiety and depression [16] that often co-occur
with USD.
A Cochrane review on non-pharmacological interven-
tions for MUPS and somatoform disorders identified
eight studies that recruited patients from primary care
[14]. However, in only two of these studies treatment
was actually performed in the primary care setting [17].
In one study [18], psychologists from secondary care
performed a CBT-based group training within general
practices. This training proved to be effective in increas-
ing physical and emotional functioning and quality of
life. Another study also offered a group intervention in
general practice, but the treatment was given by specific-
ally trained GPs and psychosomatic specialists [17]. This
intervention was effective in improving mental but not
physical functioning. However, the group formats may
not appeal to all patients and take considerable time.
Less robust evidence shows that psychotropic medi-
cation, such as antidepressants, may also have some
effect on the symptoms but these can induce depend-
ence and may have side effects [19]. Also, a recent
pilot study on a brief, multimodal psychosomatic ther-
apy, combining physical and psychological components
and delivered by physiotherapists showed improvement
in perceived symptom severity, somatization and
hyperventilation, but larger trials are needed to draw
further conclusions [20].
Meanwhile, patients with USD frequently visit their
GP [12]. However, to support and treat these patients
can be a challenging task [21, 22]. GPs may feel power-
less because they cannot find a somatic cause for the
physical symptoms with which these patients typically
present, and the patients themselves may fear serious
disease [23]. In some cases, this may lead to unnecessary
referrals to medical specialists for diagnostic and thera-
peutic purposes [24, 25]. Although GPs recognise the
need to discuss psychological issues with these patients,
this is often not feasible due to time constraints or GPs
may feel ill-equipped to do so themselves [21]. Know-
ledge about treatment of USD in primary care and its
cost-effectiveness in comparison with usual care is
lacking.
Currently, the contribution of the mental health nurse
practitioner (MHNP) within general practices in The
Netherlands is increasing. A part of mental health care,
in the form of short psychological treatment or coaching
sessions, is taken over from the GP by the MHNP.
MHNPs work within the general practice, and are
trained to provide short-term psychological treatment.
They are seemingly in a good position to offer psycho-
logical help to patients with USD in a more accessible
way, provided such tasks are clear and there is evidence
that such extra care is effective. However, they do not
yet have a standard evidence-based protocol for treating
these patients. We will, therefore, adapt an existing and
effective secondary care protocol for primary care. To
the best of our knowledge no previous research on the
effectiveness of individual treatment conducted by pri-
mary care health care workers, such as MHNPs, has
been executed yet.
The aim of this study is to examine the effectiveness
and cost-effectiveness of a short CBT-based psychological
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treatment for patients with USD provided by MHNPs, in
comparison with usual care.
Methods/design
This protocol was developed in accordance with the
Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Statement. For the
SPIRIT Figure see Additional file 1 and for the SPIRIT
Checklist see Additional file 2. We will conduct a
parallel-group, multicentre, cluster randomised con-
trolled trial in 39 primary care centres (a list of the par-
ticipating centres is provided in Additional file 3).
Cluster randomisation will take place at the MHNP and
general practice level in order to avoid contamination
between the intervention and control conditions. Clus-
ters will be composed by matching MHNPs to all par-
ticipating general practices where the MHNP works and
to all other MHNPs who also work in these general
practices. The entire cluster consisting of one or more
MHNPs and general practices will then be randomly
assigned to the intervention or to care as usual (CAU)
group, prior to the inclusion of patients. An independent
statistician, not involved in the selection of the practices
and MHNPs, will carry out the randomisation. In order
to balance the size of the intervention and CAU groups,
randomisation will be stratified according to cluster size
(small: less than 5000 patients, and large: 5000 patients
or more). Assessments will take place at baseline (T0),
during the intervention period at approximately 2
months (T1), directly after the intervention period at 4
months (T2), at 8 months (T3) and at 12 months (T4)
after baseline.
This study is registered at the Dutch Trial Registry
(NTR4686) and was approved by the VU Medical Center
Ethics Committee. It will be conducted according to the
principles of the Declaration of Helsinki (version 2013).
Important protocol modifications will be communicated
with the Dutch Trial Registry and the VU Medical Cen-
ter Ethics Committee.
Participants
Participants will be recruited from various general
practices and care groups situated in different geograph-
ical locations in The Netherlands. Patients will be eli-
gible for the study if they are 18 years or older and meet
the criteria for USD according to the Diagnostic and
Statistical Manual of Mental Disorders, version IV
(DSM-IV) [6].
Patients will be excluded from participation in the
study if they have a medical or psychological disorder
explaining their symptoms, a severe psychiatric disorder
(e.g. psychotic disorders), are currently receiving psycho-
logical treatment for USD or have poor language skills
or handicaps that prevent them from understanding the
intervention. Patients can withdraw from the study at
any time for any reason without any consequences.
Inclusion procedure
The researchers and GPs will select adult patients (aged
18 years or older) from the GP’s electronic database,
who consulted the GP with one or more symptoms from
the Robbins list [26] (Table 1) at least twice in the previ-
ous 3 months. The presented symptom does not neces-
sarily have to be the same for each visit. The Robbins list
consists of 23 physical symptoms that are associated
with functional somatic syndromes. The symptoms on
this list are likely to be medically unexplained if they
lack an accompanying ‘diagnostic’ or ‘disease’ Inter-
national Classification of Primary Care (ICPC) code (i.e.
ICPC code >70). Following this step, the participating
GPs will check the selected patients for exclusion criteria
in order to, for example, avoid inclusion of patients with
actual somatic pathology.
Patients identified as potentially eligible will then re-
ceive brief information about the study and the Patient
Health Questionnaire somatization scale (PHQ-15) [27]
from their GP. Patients who are interested in participa-
tion in the study and who have a PHQ-15 score of 5
Table 1 Symptoms from the Robbins list [26]
1. Back pain
2. Joint pain
3. Extremity pain
4. Headaches
5. Weakness
6. Fatigue
7. Sleep disturbance
8. Difficulty concentrating
9. Loss of appetite
10. Weight change
11. Restlessness
12. Thoughts slower
13. Chest pain
14. Shortness of breath
15. Palpitations
16. Dizziness
17. Lump in throat
18. Numbness
19. Nausea
20. Loose bowels
21. Gas or bloating
22. Constipation
23. Abdominal pain
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(low symptom severity) or higher will receive extensive
study information. We chose the cut-off point for low
symptom severity in order to make sure that patients
with disabling somatic complaints are not wrongly ex-
cluded at this point. Patients will then be invited to par-
ticipate in a clinical interview (Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I)) to as-
sess DSM-IV criteria for USD. Trained members of the
research team will administer the interview by tele-
phone. Patients meeting the DSM-IV criteria for USD
(the presence of one or more medically unexplained
physical symptoms that last at least 6 months and sig-
nificantly impair functioning/quality of life) will receive
an Informed Consent Form. After completing the In-
formed Consent Form and sending it back to the re-
searcher they will be included in the intervention or
CAU group based on the allocation of the MHNP and
general practice to which they belong. An overview of
the inclusion procedure is provided in Fig. 1.
The intervention
The intervention consists of extra care in addition to
usual care. We realise that, specifically for this group,
acknowledging and receiving help partly depends on
the willingness to accept psychological assistance.
Therefore, we hope that providing the intervention
in their own general practice by their own MHNP
will lower possible barriers to receiving psychological
help.
The intervention consists of six individual sessions of
30 min each. The aim of the treatment is to improve
physical functioning by helping patients cope with the
consequences of their physical symptoms and with
everyday problems in general. The rationale for the
Fig. 1 GP general practitioner, ICPC International Classification of Primary Care, PHQ-15 the Patient Health Questionnaire somatization scale, SCID-I
Structured Clinical Interview for DSM-IV Axis I disorders, USD undifferentiated somatoform disorder, MHNP mental health nurse practitioner
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intervention is based on the consequences model for
somatoform complaints [28, 29].
The consequences model for somatoform complaints
has been found to be effective in previous Dutch rando-
mised intervention studies [18, 30] and it is used in sec-
ondary mental health care. The model focusses on the
consequences or problems that arise due to somatoform
complaints rather than on the causes of somatoform
complaints which are by definition unknown. In our
study, we use the consequences model modified by
Zonneveld et al. [31]. The modified consequences model
assumes that physical symptoms lead to various conse-
quences in the daily life of patients which are in fact sur-
vival strategies in reaction to the physical symptoms.
Although these survival strategies must have been bene-
ficial at the beginning (otherwise they would not have
been developed) they can aggravate symptoms and be-
come harmful or devastating in the long run. In the
model, patients can improve (physical) functional and
quality of life by enhancing the more beneficial survival
strategies in the long run instead of the harmful ones.
Identified consequences or problems are then tackled
using cognitive behavioural problem-solving techniques
which will be learned and applied by patients in a step-
wise manner according to the steps outlined in problem-
solving therapy (PST). The goal is to help patients de-
velop more helpful survival strategies in the long run.
PST has proven to be effective for depression in primary
care and is suitable to be carried out by trained GPs or
nurses [32, 33]. Although PST has been investigated less
thoroughly in patients with USD, several studies show
promising results [18, 34, 35]. Patients become more
skilled in developing (helpful) survival strategies or
solutions by working through the following seven steps:
(1) identifying and specifying a problematic situation, (2)
setting a clear goal for resolving this problematic situ-
ation, (3) formulating as many survival strategies or so-
lutions as possible to reach this goal, (4) making a cost-
benefit analysis for each strategy or solution, (5) select-
ing the most favourable strategy or solution, (6) specify-
ing the necessary steps to implement the strategy or
solution and (7) implementing the strategy or solution
and evaluating its results. An intervention protocol was
developed in which the intervention is described in de-
tail. More information about the intervention can be re-
quested from the first author.
Training of mental health nurse practitioners
Before administering the intervention, all MHNPs in the
intervention group will receive two group-training ses-
sions of 3 to 3.5 h each, depending on the size of the
group, during a 2-week period (one session a week). A
registered clinical psychologist with broad clinical ex-
pertise in treating patients with somatoform complaints
will lead the training sessions. The aim is to train the
MHNPs in understanding and applying the intervention
according to the intervention protocol. In the first train-
ing session the theoretical background of MUPS, USD
and the modified consequences model will be given. In
the second training session, the steps of PST will be in-
troduced, explained, modelled by the clinical psycholo-
gist and finally practised by the MHNPs by applying the
treatment to a co-trainee. In between the two training
sessions, MHNPs will be asked to go through the PST
steps to solve a minor problem of their own as
homework. MHNPs will also receive a copy of the treat-
ment protocol that will serve as a guideline for the
intervention.
Feasibility testing and ongoing supervision
In order to determine whether the intervention is feasible
in practice, two MHNPs will be asked to pilot test the
protocol with a patient. Also, two patients will be asked
about their opinion on the treatment protocol. Their feed-
back will be collected and the protocol will be adjusted if
needed. During the intervention period a supervision ses-
sion with the clinical psychologist (by telephone or face-
to-face) will be offered. MHNPs can also contact the re-
searcher during the entire intervention period for any
questions regarding the treatment and the study.
Furthermore, five randomly selected MHNPs will be
asked to record all sessions with all of their patients.
The researcher (KS) will listen to the recordings and
identify topics in the obstacles encountered by the
MHNPs. The researcher will communicate this with the
clinical psychologist, so that these topics can be ad-
dressed during supervision.
Care as usual (CAU) group
Patients in the CAU group will not be offered any add-
itional specific intervention other than the care that they
would usually receive from the GP and/or MHNP, car-
ried out according to the guideline for medically unex-
plained symptoms by the Dutch College of General
Practitioners (NHG) [36].
Outcome measures
An overview of all outcome measures and the time
points of assessments can be found in Table 2.
Primary outcomes
The primary clinical outcome of this study is the im-
provement in physical functioning during the total
follow-up period measured by the physical component
summary score (PCS) of the RAND-36-item Health
Survey (RAND-36). The RAND-36 is a widely used,
valid and reliable health-related quality of life (HRQoL)
instrument comprising 36 items that assess eight health
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domains: physical functioning, role limitations caused by
physical health problems, role limitations caused by
emotional problems, social functioning, emotional well-
being, energy/fatigue, pain and general health percep-
tions [37–39]. Physical and mental health summary
scores (PCS and MCS, respectively) can be derived from
the eight scales. The raw scores are transformed into
scores ranging from 0 to 100 with a higher score indicat-
ing better functioning.
The primary outcome for the economic evaluation is
quality of life as measured by the EuroQol 5D – 5 level
version (EQ-5D-5L) [40]. The EQ-5D-5L is a standar-
dised instrument including five health domains (mobil-
ity, self-care, usual activities, pain/discomfort and
anxiety/depression). It comprises five items, one single
item referring to each domain, that are assessed on a 5-
point scale: 0 = ‘no problems with’, 1 = ‘slight problems
with’, 2 = ‘moderate problems with’, 3 = ‘severe problems
with’ and 4 = ‘unable to’. The health state indicated by
patients on the EQ-5D-5L will be converted to a utility
score using the Dutch EQ-5D-5L tariff [41]. The EQ-
5D-5L utility scores at different time points will be used
to calculate quality-adjusted life years (QALYs) using the
area under the curve method. Changes between health
states at different time points are considered to be linear.
Also, the patient is asked to rate their general health on
a 0–100 scale [40].
Societal costs will be assessed with the Trimbos and
iMTA questionnaire on Costs associated with Psychiatric
Illness (Tic-P) [42]. The Tic-P is an instrument that as-
sesses self-reported health care utilisation, medication
use, informal care, absenteeism from paid and unpaid
work, and presenteeism. The costs of the intervention
will be estimated using a bottom-up approach. For the
valuation of health care utilisation and informal care,
standard prices published in the Dutch costing guide-
lines will be used [42]. Medication use will be valued
using prices of the Royal Dutch Society for Pharmacy
(Z-index). The friction cost approach will be used to es-
timate absenteeism from paid work based on sex-
specific mean wages in the Dutch population.
Secondary outcomes
Secondary outcome measures are the eight separate sub-
scales scales of the RAND-36 (physical functioning, role
limitations caused by physical health problems, role limi-
tations caused by emotional problems, social function-
ing, emotional wellbeing, energy/fatigue, pain and
general health perceptions) [39], severity of somatization
(Patient Health Questionnaire 15-item somatic symptom
scale (PHQ-15) [27]) and depressive and anxiety symp-
toms (Hospital Anxiety and Depression Scale (HADS)
[43]). PHQ-15 is a somatic symptom scale derived from
the Patient Health Questionnaire (PHQ). It comprises
15 items, each of which can be scored from 0 = ‘not
bothered at all’ to 2 = ‘bothered a lot’, which results in a
total score ranging from 0 to 30. Higher scores indicate
higher somatic symptom severity. Scores of 5, 10 and 15
Table 2 Overview of assessment moments and outcome measurements
Instrument Baseline (T0) 2 months (T1) 4 months (T2) 8 months (T3) 12 months (T4)
Primary outcomes
Physical functioning PCS of RAND-36 x x x x
Direct and indirect costs Tic-P x x x x
Quality of life EQ-5D-5L x x x x x
Secondary outcomes
HRQoL RAND-36 subscales x x x x
Anxiety and depression HADS x x x x
Number/severity of symptoms PHQ-15 x x x x
Potential mediators
Health anxiety Whitely Index x x x
Illness perceptions Brief IPQ x x x
Cognitions and coping CBRQ x x x
Social problem-solving skills SPSI-R:S x x x
Mastery Pearlin Mastery Scale x x x
Working alliance WAI-SFa x x
PCS physical component summary score, RAND-36 RAND-36-item Health Survey, Tic-P Trimbos and iMTA questionnaire on Costs associated with Psychiatric Illness,
EQ-5D-5L EuroQol 5D – 5 level version, HRQoL health-related quality of life, HADS Hospital Anxiety and Depression Scale, PHQ-15 Patient Health Questionnaire
somatization scale, IPQ Illness Perception Questionnaire, CBRQ Cognitive and Behavioural Responses Questionnaire, SPSI-R:S Social Problem-solving Inventory
Revised: Short Form, WAI-SF Working Alliance Inventory-Short Form
aonly administered in the intervention group
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represent cut-off points for low, medium and high som-
atic symptom severity, respectively [27] .
The HADS is a 14-item instrument assessing symp-
toms of anxiety (seven items) and depression (seven
items). There are four answer categories that are
given scores of 0–3, resulting in a total score ranging
from 0 to 21 for each scale. Higher scores on the
HADS indicate more severe symptoms of anxiety and
depression. A score of 0–7 indicates no depressive or
anxiety disorder. A score of 8–10 indicates a possible
depressive or anxiety disorder, whereas a score of
11–21 indicates a probable depressive or anxiety dis-
order [43].
Patient and illness characteristics
In order to examine which patients are most likely to
benefit from the intervention, we will assess various po-
tential effect modifiers. The choice of these factors was
based in part on the Dutch multidisciplinary guideline
for MUPS and somatoform disorders which advocates
the use of three patient profiles: mild, moderate and se-
vere symptom profile [36]. Severity depends on factors
such as duration, severity and number of symptoms and
comorbidity. The potential effect modifiers selected in
this study are:
 Demographic factors: age, gender and education
(self-report)
 Illness duration (self-report)
 Severity of somatization (somatization scale of the
PHQ-15 [27])
 Physical comorbidity (self-report)
 Psychiatric comorbidity: anxiety and depression
(HADS [43])
Potential mediators
The intervention is expected to have positive effects
on physical functioning and quality of life through de-
veloping problem-solving skills and increasing adequate
coping. Moreover, health anxiety and dysfunctional
somatic causal attributions are thought to be import-
ant aggravating factors of somatoform disorders which
are reflected in the new DSM-5 criteria for somatic
symptom disorder (formerly somatoform disorders)
[44]. Therefore, the following factors will be assessed
as potential mediators:
 Problem-solving skills (Social Problem-solving
Inventory [45])
 Health anxiety (Whiteley Index [46])
 Illness perceptions (brief IPQ [47])
 Coping and beliefs about symptoms (CBRQ [48])
 Mastery (Pearlin Mastery Scale [49])
 Working alliance (WAI-SF [50])
The Social Problem-solving Inventory Revised: Short
Form (SPSI-R:S) measures an individual’s problem-
solving strengths and weaknesses. It assesses five dimen-
sions: positive problem orientation, rational problem
solving, negative problem orientation, impulsive/careless
style and avoidance style. It consists of 25 items that can
each be scored on a 5-point Likert scale (0 = ‘not at all
true for me’ to 4 = ‘extremely true for me’). Higher
scores indicate greater effective social problem-solving
skills [45].
The Whiteley Index is a short instrument measuring
health anxiety and is often used in investigating symp-
toms of hypochondria. It consists of 14 items with two
answer categories ‘yes’ and ‘no’. A higher score indicates
greater health anxiety [46].
The brief Illness Perception Questionnaire (IPQ) is
based on the widely used IPQ-R. It is designed in order
to rapidly assess the cognitive and emotional representa-
tions of illness. It comprises nine items in total. Five
items assess cognitive illness representations: conse-
quences, timeline, personal control, treatment control
and identity. Two items assess emotional representa-
tions: concern and emotions. One item assesses illness
comprehensibility. The last item is an open-ended ques-
tion assessing causal representation [47].
The Cognitive and Behavioural Responses Questionnaire
(CBRQ) measures patients’ cognitive and behavioural re-
sponses to their illness. This tool has been developed to
measure specific cognitions and coping styles in patients
with physical symptoms. It consists of 41 items that can be
rated on a 5-point Likert scale ranging from ‘strongly
disagree’ to ‘strongly agree’. These items add up to four
cognitive subscales: catastrophising, damaging beliefs,
embarrassment avoidance and symptom focussing; and
two behavioural subscales: all-or-nothing behaviour and
avoidance/resting behaviour [48].
The Pearlin Mastery Scale measures the level of per-
ceived control, or mastery, over situations in one’s life. It
comprises seven items that are scored on a 5-point
Likert scale, ranging from ‘completely disagree’ to
‘completely agree’ [49].
The Working Alliance Inventory-Short Form (WAI-SF)
is a shortened version of the Working Alliance Inventory
(WAI). It is used to measure the therapeutic alliance in an
ongoing client-therapist interaction. It comprises 12 items
that are scored on a 5-point Likert scale, ranging from
‘never or rarely’ to ‘very often’ [50].
Factors influencing implementation
Non-response and patient satisfaction
Patients who do not want to participate in the study
will be asked for reasons for non-participation. Partici-
pating patients will receive questions about satisfaction
with the content and relevance of the treatment at the
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4-month follow-up. The questions will cover topics
such as: patients’ expectations and needs prior to
treatment; whether the treatment lived up to their ex-
pectations; whether patients considered themselves to
be the target audience (suffering from USD); patients’
reasons for participating; whether the treatment helped
in the short and the long term; satisfaction with the
duration of the treatment and whether they would rec-
ommend the treatment to someone else in the future.
The above questions will be assessed using a 5-point
Likert scale ranging from 1 = ‘very satisfied’ to 5 = ‘very
unsatisfied’. Also, reasons for dropout will be assessed.
Evaluation MHNPs
The MHNPs in the intervention group will receive a
questionnaire to evaluate their opinion about the con-
tent and relevance of the treatment. The questions will
cover topics such as whether MHNPs felt the treatment
was effective for the patients; whether the intervention
protocol was useful to the MHNPs and whether they
followed the protocol as they were asked to do. Potential
reasons for non-compliance will be explored. The ques-
tions on the opinions of the MHNPs will also be
assessed on a 5-point Likert scale. Additionally, MHNPs
will be interviewed by telephone or in person to gain
insight into factors that they deem relevant for success-
ful implementation of the intervention in the future and
what possible barriers they identify. The interviews will
be recorded and transcribed for analysis.
Handling and storage of data and documents
Data will be collected and stored digitally using the
web database NetQuestionnaires. This database treats
data with strict confidence and does not disclose data
to any third parties without permission of the user.
NetQuestionnaires also takes safety measures for col-
lecting, storing and processing data to prevent un-
authorised access. In case people prefer a paper
version of the questionnaires, this will be sent by
regular mail. The completed paper questionnaires will
be stored in a locked closet at the Department of
General Practice and Elderly Care Medicine. When
working with data, subjects will be assigned with a
code. The code list will be safeguarded by the princi-
pal investigator. Only the principal investigator and
research assistants will be able to access the source
data. Data will be kept for 15 years.
Power calculation/sample size calculation
We based the sample size calculation on an expected in-
crease in the primary clinical outcome PCS of the
RAND-36 during the total follow-up period (4 and 12
months after baseline). Based on previous findings, we
aim to detect a clinically relevant effect size of 0.4. This
effect size was previously shown to be feasible in a simi-
lar population [18]. The clinically relevant difference on
the PCS ranges from 3 to 5 points [51]. Based on an es-
timate of the standard deviation of the PCS score of 10
[52], our effect size corresponds to a 4-point difference
between the intervention group and the CAU group. We
assume a two-sided significance level of 5% and a power
of 80%. The ratio of the number of subjects in the com-
pared groups is 1:1 and there are two measurements of
follow-up for our primary outcome. Although we as-
sume that the results will be similar on both repeated
measurements, we opted for a more conservative correl-
ation coefficient of 0.5. Using linear mixed models with
these values leads to a sample size of n = 74 patients per
condition.
However, since our study is a cluster randomised con-
trolled trial, we applied an additional correction for the
‘design effect’ [53] with an expected average cluster size
of four. As previous research found that 90% of intra-
class correlation coefficients (ICCs) in primary care re-
search are smaller than 0.055 [54], we chose an ICC of
0.05. After applying the correction, the sample size re-
sulted in n = 85 patients (1.15 × 74) per condition. Tak-
ing a potential dropout rate of 20% into account, we aim
to include 106 (85/0.8) patients in each condition.
Statistical analyses
Primary outcomes
Differences in the change scores between the inter-
vention group and the CAU group on the PCS of the
RAND-36 will be analysed with linear mixed models
according to the intention-to-treat principle as out-
lined in the Consolidated Standards of Interventional
Trials (CONSORT) Statement with extension to clus-
ter randomised trials [55]. This analysis technique al-
lows for the clustering of patients within MHNPs and
for dependence of observations within individuals
over time.
Secondary outcomes
Differences in change scores between the intervention
group and the CAU group on the eight separate scales
of RAND-36, HADS and PHQ-15 (secondary outcome
measures) will also be analysed with linear mixed models
according to the intention-to-treat principle.
Economic evaluation
Cost-effectiveness analysis (CEA): both a cost-
effectiveness and cost-utility analysis will be performed
from a societal perspective. The time period of the eco-
nomic evaluation will be 12 months; therefore, discount-
ing is not necessary. Sensitivity analyses will be
performed to assess the robustness of the results using
different assumptions regarding costs and effects.
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Societal costs will be related to the following effect
measures in the economic evaluation:
(1) Physical functioning as measured by the RAND-36
(2) Quality-adjusted life years (QALYs) based on the
Dutch tariff for the EuroQol (EQ-5D-5L) [41]
(3) Severity of somatization (PHQ-15) and mental
health (HADS)
The analysis will be done according to the intention-
to-treat principle. Missing cost and effect data will be
imputed using a multiple imputation technique. Incre-
mental cost-effectiveness ratios (ICERs) will be calcu-
lated by dividing the difference in mean total costs
between the groups, by the difference in mean effects
between the groups. Bootstrapping with 5000 replica-
tions will be used to estimate 95% confidence intervals
around cost differences and the uncertainty surrounding
the ICERs. Rubin’s rules will be used to pool the results
from the different multiply imputed datasets. Uncer-
tainty surrounding the ICERs will be graphically pre-
sented on cost-effectiveness planes. Cost-effectiveness
acceptability curves showing the probability that the
intervention was cost-effective in comparison with usual
care for a range of different ceiling ratios will also be es-
timated [56]. We will adjust for confounders and effect
modifiers, when necessary.
Budget impact analysis (BIA): in the BIA, the cost-
effectiveness of the short-term psychological interven-
tion and usual care will be extrapolated using a simple
Markov model over a period of 5 years based on the es-
timates obtained from the proposed study. Societal, gov-
ernment and insurer perspectives will be considered.
Different scenarios will be evaluated including the fol-
lowing: (1) the intervention is not implemented, i.e. all
patients receive usual care, (2) the intervention is offered
to the whole patient population, (3) the intervention is
implemented over a period of 4 years (25% of the patient
population per year) and (4) the intervention is only of-
fered to specific subgroups of the potential patient popu-
lation. These subgroups will be defined based on the
results of the study (e.g. subgroups that particularly
benefitted from the intervention).
The total number of patients eligible for the interven-
tion will be estimated based on Dutch incidence and
prevalence rates of USD. Resource utilisation will be cal-
culated by multiplying the number of eligible patients
with the resource utilisation rates obtained from the
cost-effectiveness analysis. Different prices will be used
to value resource use depending on the perspective of
the analysis: Dutch standard costs for the societal per-
spective, actual Dutch Healthcare Authority (NZA) tar-
iffs for the government perspective, and average NZA
tariffs for the insurer perspective. Both resource use and
annual costs will be presented over a 5-year period for
all perspectives. Aggregated and disaggregated (e.g. GP
care, secondary care, and productivity losses) total costs
per year will be presented for the different perspectives
and scenarios.
Analysis of patients most likely to benefit from the
intervention: if power allows, interaction terms between
potential effect modifiers (e.g. severity, comorbidity,
gender) and group allocation will be tested in mixed re-
gression models. In case of insufficient power, only ex-
ploratory analyses will be done.
Mediation analyses: mediation analyses will be con-
ducted to determine whether the intervention affected
physical functioning through changes in problem-solving
skills, health anxiety, illness perceptions, coping, mastery
and/or working alliance. The Krull and MacKinnon
method [57] will be used for this purpose.
Factors influencing implementation: data will be ob-
tained on participation rate, satisfaction with the inter-
vention and characteristics of non-responders. Data
collected from non-responders will be limited to demo-
graphic characteristics, such as age and gender and rea-
sons for not participating in the study. Impeding and
facilitating factors for implementation as observed by
MHNPs will be ascertained by conducting interviews
with the latter. The interviews will be transcribed verba-
tim. The transcripts will be analysed by coding the texts
using Atlas.ti and themes will be identified and
described.
Discussion
To date, this is the first study to evaluate the effective-
ness and cost-effectiveness of a short CBT-based
treatment provided by MHNPs for patients with undif-
ferentiated somatoform disorder in primary care versus
usual care. The aim of the treatment is to improve phys-
ical functioning by increasing problem-solving skills to
cope with consequences of the physical symptoms and
with everyday problems in general. We assume that
higher physical functioning and quality of life will result
in lower health care-related and work-related costs.
A strength of this study is that the intervention is pro-
vided within the patients’ own general practices. Given
the prevalence of USD and the large societal costs that
accompany this disorder, there is an urgent need to pro-
vide easily accessible and affordable treatment for pa-
tients with USD. A previous study showed that
providing psychological help in general practice was ef-
fective in improving quality of life [18]. However, the
intervention in this study was conducted in a group set-
ting by psychologists from secondary care who offered
treatment to patients in general practice. This might not
always be feasible and time-efficient. MHNPs, working
in general practices and trained in providing (short)
Sitnikova et al. Trials  (2017) 18:206 Page 9 of 13
psychological treatment, are in a much more convenient
position to help patients.
Furthermore, receiving psychological treatment in the
patients’ general practice may create a safe and low-
threshold environment for patients with USD, especially
those who would otherwise not seek psychological help
in the mental health care setting. Also, by focussing on
the consequences and not on the causes of physical
symptoms, the possible struggle about the cause of the
symptoms is avoided. Regardless of the cause, patients
suffer from consequences of USD. This approach may
create more acceptance from the patients.
By testing our intervention directly within general
practices and with MHNPs who are already employed
there, this study has a high clinical relevance. If success-
ful, the intervention is likely to be easily implemented in
daily practice as the number of MHNPs employed in the
general practices is growing. This is especially relevant
in The Netherlands, as more emphasis is being placed
on provision of mental health care services in general
practice as a result of organisational changes in health
care services.
Additionally, the current intervention combines a
cognitive behavioural theoretical framework with PST
intervention techniques for somatoform disorders. To
date, PST has been widely investigated in depression
[32, 58, 59] but rarely in somatoform disorders. One
preliminary study containing 11 subjects who received
PST found that PST was acceptable to patients and
reduced symptoms, hypochondriacal preoccupation
and psychiatric morbidity [35]. Another study investi-
gated PST in 162 patients and found a positive impact on
symptoms, functioning and costs, but in this study PST
was combined with other CBT techniques [18].
A possible limitation to our study is that we use the
diagnosis undifferentiated somatoform disorder (USD)
as defined by the DSM-IV. The fifth edition of the DSM
(DSM-5) has a new classification for the previous cat-
egory somatoform disorders. Previously, the category of
somatoform disorders included somatization disorder,
undifferentiated somatoform disorder, conversion dis-
order, pain disorder, hypochondriasis, body dysmorphic
disorder and somatoform disorder not otherwise speci-
fied. All of these somatoform disorders except hypo-
chondriasis, body dysmorphic disorder and conversion
disorder have now been categorised under somatic
symptom disorder (SSD). Furthermore, for the classifica-
tion of SSD the somatic symptoms do not have to be
medically unexplained. Our study was designed and
funded before DSM-5 was introduced. SSD is a new
DSM-5 classification and issues such as its usefulness
and accuracy are currently a topic of debate in the field
in addition to proposals for modifications of the criteria
for SSD [60–62]. Moreover, since its introduction, the
DSM-5 has not yet been widely used in research and
practice, and no appropriate diagnostic instrument
equivalent to the SCID or the Mini International
Neuropsychiatric Interview (MINI) was available at the
time of recruitment of patients. Therefore, for practical
reasons it was impossible to diagnose patients reliably
and validly according to the DSM-5. Recently the Health
Preoccupation Diagnostic Interview (HPDI), a new
structured diagnostic interview for the classification of
somatic symptom disorder and illness anxiety disorder,
has been developed by Axelsson and colleagues [63].
However, this diagnostic interview has not yet been
validated.
Another limitation is that, due to the nature of the
intervention, it is not possible to blind patients,
health care providers and researchers to treatment
allocation.
A final point of consideration concerns the primary
outcome measure, the physical component summary
score (PCS) of the RAND-36. The PCS is a general
physical functioning scale, comprising subscales measur-
ing physical aspects of health. Because the PCS is a sum-
mary score, the total score may be somewhat insensitive
to change, as potential changes on the separate subscales
may not lead to a difference in the total score. This may
make it more difficult to detect an effect on the PCS.
However, several previous studies have successfully used
the PCS scale as a primary or secondary outcome and
were able to detect change [18, 64–67]. Despite potential
shortcomings, we also chose the PCS as the primary out-
come measure, because a more specific measure, such as
the subscale ‘physical pain’ of the RAND-36, may focus
on only a part of physical functioning, whereas we aim
to investigate physical functioning in a more generic
manner. After all, the aim of the intervention is not to
reduce the symptoms, but to improve physical function-
ing as a whole. We will also separately investigate the
changes on the separate subscales as a secondary out-
come in order to see whether more specific changes take
place.
Overall, if this study shows that the treatment is ef-
fective and cost-effective, the treatment could result
in great benefits in primary care by making psycho-
logical treatments more available to patients with
USD and providing broader treatment possibilities for
primary care professionals. Quality of life of patients
with USD may be improved and health care costs
may be reduced.
Trial status
The collection of data started in November 2015. Study
results are expected to be available in April 2018. The
recruitment of participants was ongoing at the time of
manuscript submission.
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